Walleye Trading
RYTM icon

Walleye Trading’s Rhythm Pharmaceuticals RYTM Stock Holding History

Walleye Trading’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,395
Closed -$419K – 5313
2023
Q2 		$419K Buy
+25,395
New +$458K ﹤0.01% 2883

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Trading's RYTM Position: Q3 2023 in Review

Walleye Trading sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2023, closing a stake of 25,395 shares — an estimated $419K sold.

Walleye Trading first reported a position in RYTM in Q2 2023 and held it in 1 quarter. The position peaked at $419K in Q2 2023. 143 funds tracked by Wall St. Rank hold RYTM as of Q3 2023.

  • Walleye Trading reported no remaining Rhythm Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Walleye Trading sold 25,395 Rhythm Pharmaceuticals shares in Q3 2023, an estimated $419K.
  • Walleye Trading first reported a position in Rhythm Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Walleye Trading's Rhythm Pharmaceuticals position peaked at $419K in Q2 2023.
  • 143 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2023.

Based on Walleye Trading's 13F filing for Q3 2023, filed 14 Nov 2023.